Sunday, November 12, 2017 7:27:53 PM
People seem to forget our biggest study is 20 people for our phase 1/2 in hip fracture. We have NO evidence with any substantial numbers with humans. You can enjoy phase 3 trials starting, but in essence, they are with phase 2 numbers. Our results in the first actual study with some significant numbers will only come from the IC trial early next year.
So until we get those numbers from 172 subjects from I/C, we are in limbo imo. So until those numbers are released, we really are just a phase 2 at most, company when it comes to all else aside from ARS trial. Maybe that's the reason our price is where we are at. Just thought of that this evening unfortunately. Each phase eliminates a vast proportion of candidates, so until we get those results early next year, we will remain so. Unless ARS kicks in.
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM